UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 11.

Happold, C; Gorlia, T; Chinot, O; Gilbert, M R; Nabors, L B; Wick, W; Pugh, S L; Hegi, M; Cloughesy, T; Roth, P; Reardon, D A; Perry, J R; Mehta, M P; Stupp, R; Weller, M (2016). Reply to F. Felix et al and M.F. Fay et al. Journal of Clinical Oncology, 34(25):3107-3108.

Happold, C; Gorlia, T; Chinot, O; Gilbert, M R; Nabors, L B; Wick, W; Pugh, S L; Hegi, M; Cloughesy, T; Roth, P; Reardon, D A; Perry, J R; Mehta, M P; Stupp, R; Weller, M (2016). Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. Journal of Clinical Oncology, 34(7):731-739.

Mason, M; Laperriere, N; Wick, W; Reardon, D A; Malmstrom, A; Hovey, E; Weller, M; Perry, J R (2016). Glioblastoma in the elderly: making sense of the evidence. Neuro-Oncology Practice, 3(2):77-86.

Reardon, D A; Weller, M (2015). Dedication: Andrew T. Parsa. Neuro-Oncology, 17 Suppl:vii2.

Okada, H; Weller, M; Huang, R; Finocchiaro, G; Gilbert, M R; Wick, W; Ellingson, B M; Hashimoto, N; Pollack, I F; Brandes, Al A; Franceschi, E; Herold-Mende, C; Nayak, L; Panigrahy, A; Pope, W B; Prins, R; Sampson, J H; Wen, P Y; Reardon, D A (2015). Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncology, 16(15):e534-e542.

Reardon, D A; Weller, M (2015). Introduction. Neuro-Oncology, 17 Suppl:vii1.

Batchelor, T T; Reardon, D A; de Groot, J F; Wick, W; Weller, M (2014). Antiangiogenic therapy for glioblastoma: current status and future prospects. Clinical Cancer Research, 20(22):5612-5619.

Stupp, R; Hegi, M E; Gorlia, T; et al; Kim, C Y; Nabors, L B; Reardon, D A; van den Bent, M J; Hicking, C; Markivskyy, A; Picard, M; Weller, M (2014). Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, 15(10):1100-1108.

Galanis, E; Wu, W; Cloughesy, T; Lamborn, K; Mann, B; Wen, P Y; Reardon, D A; Wick, W; Macdonald, D; Armstrong, T S; Weller, M; Vogelbaum, M; Colman, H; Sargent, D J; van den Bent, M J; Gilbert, M; Chang, S (2012). Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncology, 13(5):e196-e204.

Weller, Michael (2012). Primary central nervous system tumors: pathogenesis and therapy. In: Norden, A D; Reardon, D A; Wen, P Y C. Primary Central Nervous System Tumors. Pathogenesis and Therapy. New York: Springer, 937.

Reardon, D A; Neyns, B; Weller, M; Tonn, J C; Nabors, L B; Stupp, R (2011). Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncology, 7(3):339-354.

This list was generated on Sun Jul 23 23:19:37 2017 CEST.